Corium International Inc (CORI) Given a $8.00 Price Target by Jefferies Group LLC Analysts
Jefferies Group LLC set a $8.00 price objective on Corium International Inc (NASDAQ:CORI) in a report issued on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on CORI. FBR & Co set a $12.00 price target on Corium International and gave the company a buy rating in a report on Tuesday, February 14th. Cantor Fitzgerald set a $10.00 price target on Corium International and gave the company a buy rating in a report on Tuesday, February 14th. Needham & Company LLC reduced their price target on Corium International from $12.00 to $10.00 and set a buy rating for the company in a report on Tuesday, February 14th. Zacks Investment Research raised Corium International from a sell rating to a hold rating in a report on Thursday, February 16th. Finally, Leerink Swann reissued a buy rating on shares of Corium International in a report on Wednesday, January 4th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $10.36.
Shares of Corium International (NASDAQ:CORI) traded down 2.17% during midday trading on Thursday, hitting $4.50. The stock had a trading volume of 69,465 shares. Corium International has a one year low of $2.67 and a one year high of $8.33. The firm has a 50 day moving average price of $4.03 and a 200 day moving average price of $4.35. The stock’s market cap is $131.51 million.
Corium International (NASDAQ:CORI) last posted its quarterly earnings results on Monday, February 13th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.04. The business earned $7 million during the quarter, compared to analyst estimates of $8.07 million. Corium International had a negative net margin of 116.26% and a negative return on equity of 359.24%. On average, equities analysts forecast that Corium International will post ($1.60) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Financial Market News and is the property of of Financial Market News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.financial-market-news.com/2017/04/21/corium-international-inc-cori-given-a-8-00-price-target-by-jefferies-group-llc-analysts.html.
A hedge fund recently bought a new stake in Corium International stock. Senzar Asset Management LLC acquired a new stake in Corium International Inc (NASDAQ:CORI) during the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 1,576,766 shares of the biopharmaceutical company’s stock, valued at approximately $6,402,000. Corium International comprises about 1.7% of Senzar Asset Management LLC’s holdings, making the stock its 18th largest position. Senzar Asset Management LLC owned about 5.40% of Corium International as of its most recent filing with the SEC. 67.75% of the stock is currently owned by institutional investors and hedge funds.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc and related companies with MarketBeat.com's FREE daily email newsletter.